CLOVER Study: Vaccine for Clostridioides difficile Infection in Older Adults
Author Information
Author(s): Donskey Curtis, Dubberke Erik R, Klein Nicola P, Liles Elizabeth G, Szymkowiak Katarzyna, Wilcox Mark H, Lawrence Jody, Bouguermouh Salim, Zhang Haiying, Koury Kenneth, Bailey Ruth, Smith Helen M, Lockhart Stephen, Lamberth Erik, Kalina Warren V, Pride Michael W, Webber Chris, Anderson Annaliesa S, Jansen Kathrin U, Gruber William C, Kitchin Nicholas
Primary Institution: Pfizer, Inc
Hypothesis
Does the PF-06425090 vaccine reduce the incidence of Clostridioides difficile infection in adults aged 50 and older at increased risk?
Conclusion
The PF-06425090 vaccine was safe and well tolerated, but it did not meet the primary efficacy endpoint of reducing the incidence of Clostridioides difficile infection.
Supporting Evidence
- Vaccine efficacy for first primary CDI that required medical attention was estimated at 100%.
- Median CDI duration was lower with the vaccine compared to placebo.
- Local reactions were more frequent in vaccine recipients, but most were mild to moderate.
Takeaway
A new vaccine was tested to see if it could help prevent a serious infection in older adults, but it didn't work as well as hoped.
Methodology
This phase 3 observer-blinded study randomized participants to receive either the vaccine or a placebo in a 1:1 ratio, with follow-up for CDI episodes.
Potential Biases
Potential bias due to self-reported stool samples and the inability to confirm all CDI cases through medical attention.
Limitations
The study could not distinguish between community- and healthcare-associated CDI, and stool sample collection methods may have introduced variability.
Participant Demographics
79.2% White, 51.5% female, mean age 68 years, with most participants from North America.
Statistical Information
Confidence Interval
96.4% CI, −38.7% to 66.6%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website